IL17A and neoplasm: Moreover, genetic engineering of CAR T cells to express interleukine-17 (IL-17) and CCL19, which facilitate T-cell proliferation and stimulate immune cell chemotaxis, respectively, resulted in improved survival in a mouse tumor model [5].